Humacyte, Inc.
Close on Oct 19, 2026
- Market cap
- $93.93M
- P/E (TTM)
- –
- Dividend yield
- –
About Humacyte
Biological Products, (No Diagnostic Substances), SIC 2836
Humacyte, Inc. is a biotechnology company focused on developing and commercializing bioengineered human acellular vessels and tissue engineering technologies. The company operates in program areas and reportable segments that include vascular trauma, arteriovenous (AV) access for hemodialysis, and peripheral arterial disease (PAD). Its medical technologies are targeted toward patients requiring vascular repair, replacement, or reconstruction across acute trauma care and vascular disease treatments.
The provided filing text comprises XBRL reporting taxonomy elements and accounting entries covering product categories, research and development activities, and collaborative relationships with institutions such as Yale University and Duke University. The document notes operations subject to state and local jurisdictions, but it does not disclose specific operational scale metrics, physical facility counts, country operations, or the location of corporate headquarters.
Summary of the business section of Humacyte's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Humacyte, Inc.
- Headquarters
- Durham, NC
- Address
- 2525 East North Carolina Highway 54 27713
- Phone
- (919) 313-9633
- Employees
- 184, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Raleigh, North Carolina
Stock & identifiers
- Ticker
- HUMA
- Exchange
- Nasdaq
- IPO date
- Sep 18, 2020
- Shares outstanding
- 278M, Aug 10, 2026
- Public float
- $280.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 2-for-1, Nov 15, 2021
- SEC CIK
- 1818382
- CUSIP
- 44486Q103
- ISIN
- US44486Q1031
- EIN
- 85-1763759
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Laura E. Niklason | President, CEO and Director | 1,392,091 |
| Shamik J. Parikh | Chief Medical Officer | 272,713 |
| Dale A. Sander | CFO and Chief Corp. Dev. Off | 307,813 |
| William John Scheessele | Chief Commercial Officer | 22,018 |
| Heather Ledbetter Prichard | Chief Operating Officer | 0 |
| Yang Cao | Chief Regulatory Officer | – |
| Paul Brian Kuznik | Director | 222,238 |
| D. Scott Coward | Director | – |
| Keith Anthony Jones | Director | 50,000 |
| Emery N. Brown | Director | – |
| Kathleen Sebelius | Director | 148,025 |
| Brady W. Dougan | Director | 1,392,091 |
| Max N. Wallace | Director | 64,555 |
| Susan Richards Windham-Bannister | Director | – |
| Michael T. Constantino | Director | 43,950 |
| Diane Seimetz | Director | – |
| John Philip Bamforth | Director | – |
| Charles Bruce Green | Director | 8,400 |
| Todd Pope | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Niklason | $5.23M | -$725.04K | $2.11M | $34 | – |
| FY2024 Dr. Niklason | $905.44K | $2.90M | $678.02K | $178 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 184 employees, all of whom were full-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 25, 2026 | Delisting | Notice of delisting from exchange (Form 25) |
| Jul 31, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 8, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 30, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 30, 2021 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 26, 2021 | Delisting | Notice of delisting from exchange (Form 25) |
| Aug 26, 2021 | Name change | Name changed from Alpha Healthcare Acquisition Corp. to Humacyte, Inc. |
| Mar 23, 2021 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Sep 18, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 17, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |